Table 2.
Characteristics of patients receiving allogeneic transplantation for neuroblastoma between 1990-2007 and reported to the CIBMTR
| Characteristics of patients | Did not receive prior auto, N (%) |
Received prior auto, N (%) |
|---|---|---|
| Number of patientsa | 35 | 31 |
| Number of centers | 24 | 19 |
| Age at transplant, median (range), years | 5 (2-39) | 7 (1-32) |
| 0 – 5 | 18 (51) | 7 (23) |
| 6 -10 | 9 (26) | 20 (65) |
| 11 – 20 | 5 (14) | 3 (10) |
| > 20 | 3 ( 9) | 1 ( 3) |
| Male sex | 17 (49) | 12 (39) |
| Karnofsky score prior to TX | ||
| < 90% | 13 (37) | 9 (29) |
| ≥ 90% | 21 (60) | 20 (65) |
| Unknown | 1 (3) | 2 (6) |
| Time from diagnosis to allogeneic transplant | ||
| Median (range), months | 11 (5-97) | 27 (9-76) |
| 0 – 6 | 3 ( 9) | 0 |
| 7 12 | 17 (49) | 3 (10) |
| 13 – 24 | 7 (20) | 5 (16) |
| 25 – 36 | 2 (6) | 13 (42) |
| > 36 | 6 (17) | 10 (32) |
| Had prior autologous transplant Time from autologous transplant to allogeneic transplant |
||
| Median (range), months | 19 (1-68) | |
| 0 - 12 | NA | 8 (26) |
| 13 - 24 | 12 (39) | |
| 24 – 36 | 11 (35) | |
| Disease status prior to transplant | ||
| CR | 9 (26) | 5 (16) |
| Very good partial response | 3 ( 9) | 4 (13) |
| Partial response | 9 (26) | 7 (23) |
| Minimal response | 1 (3) | 1 (3) |
| No response | 4 (11) | 1 (3) |
| Progressive disease | 3 ( 9) | 5 (16) |
| Unknown | 6 (17) | 8 (26) |
| Conditioning regimen | ||
| TBI + other | 18 (51) | 10 (32) |
| Bu + CY ± other | 3 ( 9) | 1 ( 3) |
| CY + other | 4 (11) | 6 (19) |
| Bu + Fludara ± other | 2 ( 6) | 6 (19) |
| Bu + other | 1 ( 3) | 2 ( 6) |
| Fludara + Melphalan | 1 ( 3) | 6 (19) |
| Melphlan + other | 5 (14) | 0 |
| Etopside + Carboplatin | 1 ( 3) | 0 |
| Donor recipient HLA match | ||
| HLA-identical sibling | 18 (51) | 10 (32) |
| Other related donor | 3 ( 9) | 2 ( 6) |
| Matched unrelated donor | 0 | 5 (16) |
| Mismatched unrelated donor | 14 (40) | 13 (42) |
| Matching unknown, unrelated donor | 0 | 1 ( 3) |
| Graft source | ||
| BM | 16 (46) | 11 (35) |
| PBSC | 4 (11) | 8 (26) |
| Cord Blood | 15 (43) | 12 (39) |
| Year of transplant | ||
| 1990 – 1994 | 14 (40) | 1 ( 3) |
| 1995 – 1999 | 5 (14) | 8 (26) |
| 2000 – 2004 | 12 (34) | 9 (29) |
| 2005 – 2007 | 4 (11) | 13 (42) |
| GVHD prophylaxis | ||
| T-cell depletion | 3 ( 9) | 1 ( 3) |
| MTX + CSA ± other | 8 (23) | 7 (23) |
| MTX ± other | 4 (11) | 2 ( 6) |
| CSA ± Other | 17 (49) | 17 (55) |
| Fk506 ± Other | 0 | 2 (6) |
| Unknownb | 3 (9) | 2 (6) |
| Previous bone marrow involvement | ||
| No | 4 (11) | 6 (19) |
| Yes | 10 (29) | 14 (45) |
| Unknown | 21 (60) | 11 (35) |
| Previous CNS involvement | ||
| No | 12 (34) | 19 (61) |
| Yes | 2 (6) | 1 (3) |
| Unknown | 21 (60) | 11 (35) |
| Metastases present at diagnosis | ||
| No | 1 ( 3) | 2 ( 6) |
| Yes | 14 (40) | 16 (52) |
| Missing | 20 (57) | 13 (42) |
| disease INSS stage at diagnosis | ||
| Stage 1 | 1 ( 3) | 0 |
| Stage 3 | 4 (11) | 3 (10) |
| Stage 4 | 10 (29) | 14 (45) |
| Missing | 20 (57) | 14 (45) |
| Number of sites of disease at allogeneic transplant | ||
| 1 | 1 ( 3) | 3 (10) |
| 2 | 3 ( 9) | 3 (10) |
| 3 | 2 ( 6) | 2 ( 6) |
| 4 | 1 ( 3) | 2 ( 6) |
| Missing | 16 (46) | 12 (39) |
| NA (disease status was CR, VGPR) | 12 (34) | 9 (29) |
| Chemo sensitive to last line of therapy | ||
| No | 2 ( 6) | 1 ( 3) |
| Yes | 8 (23) | 12 (39) |
| did not receive chemotherapy as last line of therapy | 2 ( 6) | 0 |
| Missing | 23 (66) | 18 (58) |
| Radiotherapy given as part of initial treatment | ||
| No | 12 (34) | 12 (39) |
| Yes (primary tumor bed after resection as sit of radiotherapy) |
1 ( 3) | 2 ( 6) |
| Unknown | 22 (63) | 17 (55) |
| Donor-recipient sex match | ||
| M – M | 9 (26) | 4 (13) |
| M – F | 9 (26) | 7 (23) |
| F – M | 8 (23) | 6 (19) |
| F – F | 8 (23) | 10 (32) |
| Unknown | 1 ( 3) | 4 (13) |
| Donor-recipient CMV status | ||
| −/− | 17 (49) | 11 (35) |
| +/− | 3 ( 9) | 3 (10) |
| −/+ | 10 (29) | 9 (29) |
| +/+ | 3 ( 9) | 4 (13) |
| Unknown | 2 ( 6) | 4 (13) |
| Median (range) follow-up c, months | 72 (3-150) | 45 (3-58) |
Abbreviations: TBI = total body irradiation; CY = cyclophosphamide; CsA = cyclosporine; MTX = methotrexate; CMV = cytomegalovirus; GVHD = graft-versus-host disease; FK506 = tacrolimus.